VSV-GP154 / Boehringer Ingelheim - LARVOL DELTA

A phase 1b study to evaluate the safety, tolerability and preliminary efficacy of a heterologous prime boost vaccination (ATP150/ATP152/ATP162, VSV-GP154) and ezabenlimab (BI 754091) in patients with pancreatic ductal adenocarcinoma. (ASCO-GI 2026) - P1 | "Funded by Boehringer Ingelheim Clinical Trial Registration Number: NCT05846516 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • P1 data • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

KISIMA-02: A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - P1 | N=94 | Recruiting | Sponsor: Amal Therapeutics | Trial completion date: Mar 2027 ➔ May 2029 | Trial primary completion date: Dec 2026 ➔ Jun 2028

Trial completion date • Trial primary completion date • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • KRAS

A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02) (clinicaltrials.gov) - P1 | N=85 | Recruiting | Sponsor: Amal Therapeutics | Phase classification: P1b ➔ P1

Phase classification • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • KRAS

A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02) (clinicaltrials.gov) - P1b | N=85 | Recruiting | Sponsor: Amal Therapeutics

New P1 trial • Gastrointestinal Cancer • Immune Modulation • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • KRAS